Search

Your search keyword '"Abraham, William T."' showing total 2,702 results
Start Over Author "Abraham, William T."
2,702 results on '"Abraham, William T."'

102. A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial

Author

Piccini, Jonathan P., Connolly, Stuart J., Abraham, William T., Healey, Jeff S., Steinberg, Benjamin A., Al-Khalidi, Hussein R., Dignacco, Patricia, van Veldhuisen, Dirk J., Sauer, William H., White, Michel, Wilton, Stephen B., Anand, Inder S., Dufton, Christopher, Marshall, Debra A., Aleong, Ryan G., Davis, Gordon W., Clark, Richard L., Emery, Laura L., and Bristow, Michael R.

Published
2018
Full Text
View/download PDF

105. Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory

Author

O’Connor, Christopher M., Psotka, Mitchell A., Fiuzat, Mona, Lindenfeld, JoAnn, Abraham, William T., Bristow, Michael R., Canos, Daniel, Harrington, Robert A., Hillebrenner, Matt, Jessup, Mariell, Malik, Fady I., Solomon, Scott D., Stockbridge, Norman, Tcheng, James E., Unger, Ellis F., Whellan, David J., Zuckerman, Bram, and Califf, Robert M.

Published
2018
Full Text
View/download PDF

108. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials

Author

Metra, Marco, Eichhorn, Eric, Abraham, William T, Linseman, Jennifer, Böhm, Michael, Corbalan, Ramon, DeMets, David, De Marco, Teresa, Elkayam, Uri, Gerber, Michael, Komajda, Michel, Liu, Peter, Mareev, Vyacheslev, Perrone, Sergio V, Poole-Wilson, Philip, Roecker, Ellen, Stewart, Jennifer, Swedberg, Karl, Tendera, Michal, Wiens, Brian, and Bristow, Michael R

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Aging, Clinical Trials and Supportive Activities, Rehabilitation, Cardiovascular, Heart Disease, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Administration, Oral, Adult, Aged, Blood Pressure, Cardiotonic Agents, Chronic Disease, Double-Blind Method, Enoximone, Exercise, Exercise Tolerance, Heart Failure, Heart Rate, Hospitalization, Humans, Kaplan-Meier Estimate, Middle Aged, Young Adult, Advanced heart failure, Inotropic agents, ESSENTIAL Investigators, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology, Clinical sciences
Abstract

AimsUse of inotropic agents in patients with heart failure (HF) has been limited by adverse effects on outcomes. However, administration of positive inotropes at lower doses and concomitant treatment with beta-blockers might increase benefit-risk ratio. We investigated the effects of low doses of the positive inotrope enoximone on symptoms, exercise capacity, and major clinical outcomes in patients with advanced HF who were also treated with beta-blockers and other guideline-recommended background therapy.Methods and resultsThe Studies of Oral Enoximone Therapy in Advanced HF (ESSENTIAL) programme consisted of two identical, randomized, double-blind, placebo-controlled trials that differed only by geographic location (North and South America: ESSENTIAL-I; Europe: ESSENTIAL-II). Patients with New York Heart Association class III-IV HF symptoms, left ventricular ejection fraction < or = 30%, and one hospitalization or two ambulatory visits for worsening HF in the previous year were eligible for participation in the trials. The trials had three co-primary endpoints: (i) the composite of time to all-cause mortality or cardiovascular hospitalization, analysed in the two ESSENTIAL trials combined; (ii) the 6 month change from baseline in the 6 min walk test distance (6MWTD); and (iii) the Patient Global Assessment (PGA) at 6 months, both analysed in each trial separately. ESSENTIAL-I and -II randomized 1854 subjects at 211 sites in 16 countries. In the combined trials, all-cause mortality and the composite, first co-primary endpoint did not differ between the two treatment groups [hazard ratio (HR) 0.97; 95% confidence interval (CI) 0.80-1.17; and HR 0.98; 95% CI 0.86-1.12, respectively, for enoximone vs. placebo]. The two other co-primary endpoints were analysed separately in the two ESSENTIAL trials, as prospectively designed in the protocol. The 6MWTD increased with enoximone, compared with placebo, in ESSENTIAL-I (P = 0.025, not reaching, however, the pre-specified criterion for statistical significance of P < 0.020), but not in ESSENTIAL-II. No difference in PGA was observed in either trial.ConclusionAlthough low-dose enoximone appears to be safe in patients with advanced HF, major clinical outcomes are not improved.

Published
2009

110. PO-02-027 RELATIONSHIP BETWEEN SEX, BODY SIZE, AND CRT BENEFIT: A PATIENT LEVEL META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Author

Friedman, Daniel J., primary, Al-Khatib, Sana M., additional, Cleland, John G., additional, Dalgaard, Frederik, additional, Fudim, Marat, additional, Abraham, William T., additional, Curtis, Anne B., additional, Gold, Michael R., additional, Kutyifa, Valentina, additional, Linde, Cecilia M., additional, Tang, Anthony S., additional, Olivas-Martinez, Antonio, additional, Inoue, Lurdes, additional, and Sanders, Gillian, additional

Published
2023
Full Text
View/download PDF

121. Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure: One-Year Outcomes From the CardioMEMS Post-Approval Study

Author

Shavelle, David M., Desai, Akshay S., Abraham, William T., Bourge, Robert C., Raval, Nirav, Rathman, Lisa D., Heywood, J. Thomas, Jermyn, Rita A., Pelzel, Jamie, Jonsson, Orvar T., Costanzo, Maria Rosa, Henderson, John D., Brett, Marie-Elena, Adamson, Philip B., and Stevenson, Lynne W.

Published
2020
Full Text
View/download PDF

125. Cardiac Resynchronization Therapy Improves Outcomes in Patients With Intraventricular Conduction Delay But Not Right Bundle Branch Block: A Patient-Level Meta-Analysis of Randomized Controlled Trials

Author

Friedman, Daniel J., primary, Al-Khatib, Sana M., additional, Dalgaard, Frederik, additional, Fudim, Marat, additional, Abraham, William T., additional, Cleland, John G.F., additional, Curtis, Anne B., additional, Gold, Michael R., additional, Kutyifa, Valentina, additional, Linde, Cecilia, additional, Tang, Anthony S., additional, Ali-Ahmed, Fatima, additional, Olivas-Martinez, Antonio, additional, Inoue, Lurdes Y.T., additional, and Sanders, Gillian D., additional

Published
2023
Full Text
View/download PDF

126. Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation

Author

Stone, Gregg W., primary, Abraham, William T., additional, Lindenfeld, JoAnn, additional, Kar, Saibal, additional, Grayburn, Paul A., additional, Lim, D. Scott, additional, Mishell, Jacob M., additional, Whisenant, Brian, additional, Rinaldi, Michael, additional, Kapadia, Samir R., additional, Rajagopal, Vivek, additional, Sarembock, Ian J., additional, Brieke, Andreas, additional, Marx, Steven O., additional, Cohen, David J., additional, Asch, Federico M., additional, and Mack, Michael J., additional

Published
2023
Full Text
View/download PDF

127. Impact of Peripheral Artery Disease in Patients With Heart Failure Undergoing Transcatheter Mitral Valve Repair: The COAPT Trial

Author

Shahim, Bahira, primary, Cohen, David J., additional, Ben‐Yehuda, Ori, additional, Redfors, Björn, additional, Kar, Saibal, additional, Lim, D. Scott, additional, Arnold, Suzanne V., additional, Li, Yanru, additional, Lindenfeld, JoAnn, additional, Abraham, William T., additional, Mack, Michael J., additional, and Stone, Gregg W., additional

Published
2023
Full Text
View/download PDF

137. Safety, usability, and performance of a wireless left atrial pressure monitoring system in patients with heart failure: the VECTOR-HF trial

Author

D'Amario, Domenico, Meerkin, David, Restivo, Attilio, Ince, Hüseyin, Sievert, Horst, Wiese, Andrea, Schaefer, Ulrich, Trani, Carlo, Bayes-Genis, Antoni, Leyva, Francisco, Whinnett, Zachary I, Di Mario, Carlo, Jonas, Michael, Manhal, Habib, Amat-Santos, Ignacio J, Del Trigo, Maria, Gal, Tuvia Ben, Ben Avraham, Binyamin, Hasin, Tal, Feickert, Sebastian, D'Ancona, Giuseppe, Altisent, Omar Abdul-Jawad, Koren, Oran, Caspi, Oren, Abraham, William T, Crea, Filippo, Anker, Stefan D, Kornowski, Ran, and Perl, Leor

Subjects
Heart Failure, Device in Heart Failure, Remote Care, Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, Digital Health, Haemodynamic Remote Monitoring
Published
2023

138. Population Study of Urban, Rural, and Semiurban Regions for the Detection of Endovascular Disease and Prevalence of Risk Factors and Holistic Intervention Study: Rationale, Study Design, and Baseline Characteristics of PURSE-HIS

Author

Thanikachalam, Sadagopan, Harivanzan, Vijayakumar, Mahadevan, Murugappapillai V., Murthy, J.S.N., Anbarasi, Chandrasekar, Saravanababu, Chidambaram S., Must, Aviva, Baliga, Ragavendra R., Abraham, William T., and Thanikachalam, Mohan

Published
2015
Full Text
View/download PDF

141. List of Contributors of Volume 3

Author

Abell, Thomas, primary, Abraham, William T., additional, Alabbad, Ali, additional, Al-Kaisy, Adnan, additional, Andréll, Paulin, additional, Andrew McKinley, Richard, additional, Angeli, Claudia A., additional, Ardell, Jeffrey L., additional, Arnold, Anthony, additional, Audu, Musa, additional, Baker, Kenneth B., additional, Barolat, Giancarlo, additional, Baskin, Jonathan Z., additional, Benderro, Girriso F., additional, Bennett, Maria E., additional, Bikson, Marom, additional, Bouton, Chad E., additional, Buckley, Una, additional, Carvalho, Sandra, additional, Cavuoto, James, additional, Chae, John, additional, Chen, Jiande D.Z., additional, Chen, Shuo, additional, Cohn, Joshua A., additional, Creasey, Graham H., additional, Czura, Christopher J., additional, Damato, Elizabeth G., additional, de Groat, William C., additional, Decker, Michael J., additional, DiMarco, Anthony F., additional, Dipietro, Laura, additional, Dmochowski, Roger R., additional, Dorman, Michael F., additional, Duarte, Rui V., additional, Durand, Dominique M., additional, Elizabeth Germany, Robin, additional, Emala, Charles, additional, Errico, J.P., additional, Faltys, Michael, additional, Franke, Manfred, additional, Fregni, Felipe, additional, French, Melanie, additional, Fritz, Jason R., additional, Gassler, John P., additional, Gonzalez Calle, Alejandra, additional, Harkema, Susan J., additional, Hassouna, Magdy, additional, Horsch, Svante, additional, Humayun, Mark S., additional, Huston, Jared M., additional, Jin, Haifeng, additional, Kapural, Leonardo, additional, Kaufman, Melissa R., additional, Kilgore, Kevin L., additional, Knutson, Jayme S., additional, Kobetic, Rudi, additional, Kowalski, Krzysztof E., additional, Kowalik, Casey G., additional, Krames, Elliot S., additional, Leite, Jorge, additional, Levine, Yaakov A., additional, Li, Yanmei, additional, Loudin, James, additional, Lu, Peter L., additional, Machado, Andre G., additional, Makowski, Nathaniel S., additional, Malde, Sachin, additional, Michael Ackermann, D., additional, Milam, Douglas F., additional, Mogilner, Alon Y., additional, Mousa, Hayat M., additional, Moynahan, Megan, additional, Murray, Drew, additional, Olofsson, Peder S., additional, Onders, Raymond P., additional, Peckham, P. Hunter, additional, Perryman, Laura, additional, Piedimonte, Fabian, additional, Prager, Joshua P., additional, Rejc, Enrico, additional, Reynolds, William S., additional, Sahai, Arun, additional, Salavatian, Siamak, additional, Schiefer, Matthew A., additional, Schneider, Marabel, additional, Schulte, Stefan, additional, Selkirk, Stephen, additional, Simis, Marcel, additional, Simon, Bruce, additional, Simon, Jesse, additional, Snyder, Jon, additional, Staats, Peter, additional, Strohl, Kingman P., additional, Thibaut, Aurore, additional, Thomson, Simon J., additional, Triolo, Ronald J., additional, Tyler, Dustin J., additional, Unal, Gozde, additional, Vasquez, Alejandra, additional, Wagner, Timothy, additional, Wathen, Connor A., additional, Weiland, James D., additional, Wilson, Blake S., additional, Wilson, Richard D., additional, Yao, Shukun, additional, Yin, Jieyun, additional, Yoruk, Ayhan, additional, and Zitnik, Ralph, additional

Published
2018
Full Text
View/download PDF

144. Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction.

Author

Yang, Mingming, Kondo, Toru, Adamson, Carly, Butt, Jawad H., Abraham, William T., Desai, Akshay S., Jering, Karola S., Køber, Lars, Kosiborod, Mikhail N., Packer, Milton, Rouleau, Jean L., Solomon, Scott D., Vaduganathan, Muthiah, Zile, Michael R., Jhund, Pardeep S., and McMurray, John J.V.

Subjects
HEART failure, HEART failure patients, VENTRICULAR ejection fraction, CARDIOMYOPATHIES, CHRONIC obstructive pulmonary disease, THERAPEUTICS
Abstract

Aim: Patients with heart failure (HF) often suffer from a range of comorbidities, which may affect their health status. The aim of this study was to assess the impact of different comorbidities on health status in patients with HF and reduced (HFrEF) and preserved ejection fraction (HFpEF). Methods and results: Using individual patient data from HFrEF (ATMOSPHERE, PARADIGM‐HF, DAPA‐HF) and HFpEF (TOPCAT, PARAGON‐HF) trials, we examined the Kansas City Cardiomyopathy Questionnaire (KCCQ) domain scores and overall summary score (KCCQ‐OSS) across a range of cardiorespiratory (angina, atrial fibrillation [AF], stroke, chronic obstructive pulmonary disease [COPD]) and other comorbidities (obesity, diabetes, chronic kidney disease [CKD], anaemia). Of patients with HFrEF (n = 20 159), 36.2% had AF, 33.9% CKD, 33.9% diabetes, 31.4% obesity, 25.5% angina, 12.2% COPD, 8.4% stroke, and 4.4% anaemia; the corresponding proportions in HFpEF (n = 6563) were: 54.0% AF, 48.7% CKD, 43.4% diabetes, 53.3% obesity, 28.6% angina, 14.7% COPD, 10.2% stroke, and 6.5% anaemia. HFpEF patients had lower KCCQ domain scores and KCCQ‐OSS (67.8 vs. 71.3) than HFrEF patients. Physical limitations, social limitations and quality of life domains were reduced more than symptom frequency and symptom burden domains. In both HFrEF and HFpEF, COPD, angina, anaemia, and obesity were associated with the lowest scores. An increasing number of comorbidities was associated with decreasing scores (e.g. KCCQ‐OSS 0 vs. ≥4 comorbidities: HFrEF 76.8 vs. 66.4; HFpEF 73.7 vs. 65.2). Conclusions: Cardiac and non‐cardiac comorbidities are common in both HFrEF and HFpEF patients and most are associated with reductions in health status although the impact varied among comorbidities, by the number of comorbidities, and by HF phenotype. Treating/correcting comorbidity is a therapeutic approach that may improve the health status of patients with HF. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

146. Stroke in patients with heart failure and reduced or preserved ejection fraction.

Author

Yang, Mingming, Kondo, Toru, Butt, Jawad H, Abraham, William T, Anand, Inder S, Desai, Akshay S, Køber, Lars, Packer, Milton, Pfeffer, Marc A, Rouleau, Jean L, Sabatine, Marc S, Solomon, Scott D, Swedberg, Karl, Zile, Michael R, Jhund, Pardeep S, and McMurray, John J V

Subjects
HEART failure patients, STROKE patients, VENTRICULAR ejection fraction, SYSTOLIC blood pressure, STROKE
Abstract

Aims Stroke is an important problem in patients with heart failure (HF), but the intersection between the two conditions is poorly studied across the range of ejection fraction. The prevalence of history of stroke and related outcomes were investigated in patients with HF. Methods and results Individual patient meta-analysis of seven clinical trials enrolling patients with HF with reduced (HFrEF) and preserved ejection fraction (HFpEF). Of the 20 159 patients with HFrEF, 1683 (8.3%) had a history of stroke, and of the 13 252 patients with HFpEF, 1287 (9.7%) had a history of stroke. Regardless of ejection fraction, patients with a history of stroke had more vascular comorbidity and worse HF. Among those with HFrEF, the incidence of the composite of cardiovascular death, HF hospitalization, stroke, or myocardial infarction was 18.23 (16.81–19.77) per 100 person-years in those with prior stroke vs. 13.12 (12.77–13.48) in those without [hazard ratio 1.37 (1.26–1.49), P < 0.001]. The corresponding rates in patients with HFpEF were 14.16 (12.96–15.48) and 9.37 (9.06–9.70) [hazard ratio 1.49 (1.36–1.64), P < 0.001]. Each component of the composite was more frequent in patients with stroke history, and the risk of future stroke was doubled in patients with prior stroke. Among patients with prior stroke, 30% with concomitant atrial fibrillation were not anticoagulated, and 29% with arterial disease were not taking statins; 17% with HFrEF and 38% with HFpEF had uncontrolled systolic blood pressure (≥140 mmHg). Conclusion Heart failure patients with a history of stroke are at high risk of subsequent cardiovascular events, and targeting underutilization of guideline-recommended treatments might be a way to improve outcomes in this high-risk population. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results